Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of GSK525762C and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas

NCT03925428 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03925428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03925428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of GSK525762C and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Withdrawn
Start date
September 18, 2020
Completion date
September 18, 2020
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced lymphoma, advanced malignant solid neoplasm, ann arbor stage iii b-cell non-hodgkin lymphoma, ann arbor stage iii t-cell non-hodgkin lymphoma, ann arbor stage iv b-cell non-hodgkin lymphoma, ann arbor stage iv t-cell non-hodgkin lymphoma, refractory b-cell non-hodgkin lymphoma, refractory lymphoma, refractory malignant solid neoplasm, refractory pancreatic carcinoma, refractory t-cell non-hodgkin lymphoma, stage ii pancreatic cancer ajcc v8, stage iia pancreatic cancer ajcc v8, stage iib pancreatic cancer ajcc v8, stage iii pancreatic cancer ajcc v8, stage iv pancreatic cancer ajcc v8, unresectable pancreatic carcinoma